CSIMarket


Gilead Sciences Inc   (GILD)
Other Ticker:  
 

Gilead Sciences Inc

GILD's Fundamental analysis








Looking into Gilead Sciences Inc growth rates, revenue grew by 2.6 % in I. Quarter 2022 from the same quarter a year ago. Ranking at No. 1447

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 25.35 %

Gilead Sciences Inc 's net profit deacreased by -99.3 % in I. Quarter 2022 year on year, to $12 millions.

More on GILD's Growth


Gilead Sciences Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Gilead Sciences Inc PEG ratio is at 0.01 , above Biotechnology & Pharmaceuticals industry PEG average of 0.
Company
17.96
PE TTM   
Industry
0
PE TTM    
Company's Price to Sales ratio is at 2.96.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 4.46.


More on GILD's Valuation
 
 Total Debt (Millions $) 26,208
 Dividend TTM ($) 2.88 $
 Dividend Yield TTM (%) 4.66 %
 Revenue/Employee (TTM) $ 2,328,136
 Net Income/Employee (TTM) $ 380,593
 Receivable Turnover (TTM) 6.47
 Tangible Book Value (Per Share $) -14.84

Gilead Sciences Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Gilead Sciences Inc PEG ratio is at 0.01 , above Biotechnology & Pharmaceuticals industry PEG average of 0.
Company
17.96
PE TTM   
Industry
0
PE TTM    
Company's Price to Sales ratio is at 2.96.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 4.46.

Gilead Sciences Inc Price to Book Ratio is at 4.08 lower than Indusry Avg. of 492.12. and higher than S&P 500 Avg. of -0.01

More on GILD's Valuation

  Market Capitalization (Millions $) 81,210
  Shares Outstanding (Millions) 1,262
  Employees 11,800
  Revenues (TTM) (Millions $) 27,472
  Net Income (TTM) (Millions $) 4,491
  Cash Flow (TTM) (Millions $) 231
  Capital Exp. (TTM) (Millions $) -661
  Total Debt (Millions $) 26,208
  Dividend TTM ($) 2.88 $
  Dividend Yield TTM (%) 4.66 %
  Revenue/Employee (TTM) $ 2,328,136
  Net Income/Employee(TTM) $ 380,593
  Receivable Turnover Ratio (TTM) 6.47
  Tangible Book Value (Per Share $) -14.84

  Market Capitalization (Millions $) 81,210
  Shares Outstanding (Millions) 1,262
  Employees 11,800
  Revenues (TTM) (Millions $) 27,472
  Net Income (TTM) (Millions $) 4,491
  Cash Flow (TTM) (Millions $) 231
  Capital Exp. (TTM) (Millions $) -661


    GILD's Profitability Comparisons
Gilead Sciences Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in I. Quarter 2022 to 2.99 % from 12.98 % in IV. Quarter.

Gilead Sciences Inc net profit margin of 0.18 % is currently ranking no. 24 in Biotechnology & Pharmaceuticals industry, ranking no. 173 in Healthcare sector and number 2338 in S&P 500.


Profitability by Segment



  Ratio
   Capital Ratio (MRQ) 2.47
  Total Debt to Equity (MRQ) 1.32
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.41
  Inventory Turnover Ratio (TTM) 4.07



Gilead Sciences Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in I. Quarter 2022 to 2.99 % from 12.98 % in IV. Quarter.

Gilead Sciences Inc net profit margin of 0.18 % is currently ranking no. 24 in Biotechnology & Pharmaceuticals industry, ranking no. 173 in Healthcare sector and number 2338 in S&P 500.

More on GILD's Key Ratios



       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CFRX's Profile

Stock Price

CFRX's Financials

Business Description

Fundamentals

Charts & Quotes

CFRX's News

Suppliers

CFRX's Competitors

Customers & Markets

Economic Indicators

CFRX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071